LBRX reports $19M Q1 loss advancing Phase 3 schizophrenia trial; material control weaknesses persist

Filed May 12, 2026 · Period ending March 31, 2026 · ~2 min read

Key Changes

• high

  Disclosure controls deemed ineffective due to unremediated material weaknesses in staffing, segregation of duties, and IT access controls—deficiencies first identified in 2024 that remain unresolved, creating ongoing risk of undetected financial misstatements.

  Controls & Procedures verify on EDGAR →
• high

  Q1 2026 net loss tripled to $19.1M from $5.3M prior year, driven by $11.2M increase in R&D spending on pivotal Phase 3 schizophrenia trial (NOVA-2) and Phase 2 bipolar depression trial (ILLUMINATE-1). Cash runway extends into Q2 2029 with $365.6M on hand.

  MD&A: Financial Results verify on EDGAR →
• high

  Company owes perpetual royalties to insiders (investors, co-founders, officers) totaling 2.75% of LB-102 net sales through 2035, then 3.25% thereafter—obligations entered in 2023 with no consideration paid, permanently reducing future product economics.

  MD&A: Royalty Obligations verify on EDGAR →